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A STUDY ON PHENOTYPIC POLYMORPHISM OF SERUM 
PARAOXONASE1 AND ACTIVITY OF SERUM 
CHOLINESTERASE IN ACUTE ORGANOPHOSPHOROUS 
COMPOUND POISONING 
Ananthi P, Uma Maheswari V, Mahalakshmi R.  
Objective:  Serum Paraoxonase1 (PON1) is involved in the metabolism of 
Organophosphorous (OP) compounds. PON1 is polymorphic and at least 
three phenotypes have been described so far. The phenotypic polymorphism 
of PON1 may affect the susceptibility of patients to OPC toxicity. This study 
is focused on the evaluation of phenotypic enzyme activities of serum 
Paraoxonase1 (PON1) and its relationship with serum Cholinesterase 
activity in 54 patients with Acute Organophosphorus compound (OPC) 
poisoning. 
Materials and Methods: Serum paraoxonase and arylesterase activities of 
PON1 were estimated in dual beam spectrophotometer. Serum 
Cholinesterase activity was measured in Semiautoanalyser. The results were 
analyzed using SPSS version 16, where ‘one way ANOVA’ was used to 
compare mean values of variables among PON1 phenotypes and correlation 
analysis was done with ‘Pearson coefficient of correlation’. 
Results: Mean values of activity of Cholinesterase, Paraoxonase, 
Arylesterase     were 2325 (SD ± 2027.19) U/L; 218.39 (SD ± 124.30) U/L; 
and 85.13 (SD ± 30.19) kU/L respectively. Activity of all three enzymes 
viz., Cholinesterase, Paraoxonase, Arylesterase varied with respect to PON1 
phenotypes. PON1 BB phenotype has high Paraoxonase and Cholinesterase 
activity whereas AA phenotype has low Paraoxonase and Cholinesterase 
activity and the AB phenotype was reported with in between activity. Serum 
Cholinesterase was correlated positively and significantly with serum 
Paraoxonase (Coefficient of Correlation, r = +0.767, with p value < 0.0001) 
as well as with serum Paraoxonase/Arylesterase activity (P/A) (Coefficient 
of Correlation, r = +0.955, with p value < 0.0001) which was used to 
determine PON1 phenotypes. 
Conclusion: To conclude, in case of Acute OPC poisoning, identification of 
PON1 phenotype can be useful to identify the susceptibility of patients to 
OPC toxicity.  
Keywords: Organophosphorus compounds, Cholinesterase, Paraoxonase1, 
PON1 Polymorphism.  
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INTRODUCTION 
Poisoning is one of the prevalent causes of poor health and mortality 
worldwide. Organophosphorus (OP) compounds used in agriculture as 
pesticides are increasing in developing countries like India. Intoxication to 
OP compounds leads to a major health problem globally1.  
Organophosphorous compounds are esters of phosphoric or 
thiophosphoric acids. Acute exposure to these compounds results in different 
grades of neuromuscular toxicity2,3 due to inhibition of Acetyl 
Cholinesterase (AChE) and Neuropathy Target Esterase (NTE)4,5. 
Organophosphorous compounds also increase the oxidative stress and 
damage the nervous and muscular tissues3,6,7. Serum Cholinesterase activity 
is a sensitive diagnostic alternative for neural Acetylcholinesterase activity. 
Serial estimation of serum Cholinesterase activity is useful in monitoring the 
disease progress and grading the severity of toxicity8. 
Paraoxonase 1(PON1) is an aryldialkylesterase synthesized in the 
liver and secreted into the blood in association with high density lipoproteins 
(HDL)9. It is involved in the detoxification of organophosphorous 
compounds and has a protective role against OPC toxicity10,11,12. It reduces 
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the oxidative stress by clearing the oxidized low density lipoproteins (LDL), 
lactones and aromatic carboxylic acid esters from blood13. 
Paraoxonase1 is a polymorphic enzyme that has three phenotypes 
namely AA, AB, BB which has low, moderate and high level of enzyme 
activity respectively. It is determined by the genotypic polymorphism of 
PON1 at the coding region Q192R14 of the genome. 
The degree and the duration of inhibition of cholinesterase activity 
depend on the level of active ‘oxon’ form of OPC in blood and tissues which 
in turn is directly related to the activity of Paraoxonase1 enzyme15. Since 
serum PON1 is a polymorphic enzyme, the susceptibility of patients to the 
toxicity of OPC varies with the level of serum Paraoxonase1 (PON1) 
activity15,16 .which is specific for a particular phenotype thereby the severity 
of poisoning and the recovery of the patients are affected by serum 
Paraoxonase1 phenotypic polymorphism. 
The present study was undertaken to identify the role of serum 
Paraoxonase1 (PON1) phenotype in patients with Acute Organophosphorous 
compound (OPC) poisoning. 
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POISONING 
Poison is a substance that causes harmful effects when administered, 
either by intentional or accidental, to a living organism by altering their 
biological structure or functions by acting at the molecular and biochemical 
level17.The rapid development in medical, industrial and agricultural fields 
introduced a new range of synthetic chemical substances to improve the 
productivity17. In addition with the naturally occurring poisons, the easy 
availability and accessibility of the synthetic compounds has now become a 
major risk for poisoning18.  
According to World Health Organization (WHO) report in 2002-2005, 
there were more than 3 million poisoning cases with 2, 20, 000 deaths 
occurred annually all around the world18.  A study done by Unikrishnan et al 
in 2005 has shown that poisoning is the fourth most common cause of 
mortality rate in India. The pattern of poisoning in a particular region is 
influenced by many factors such as availability and accessibility to the 
poison, educational and socioeconomic status of the people19. Pesticidal 
poisoning and self poisoning to them are more common in developing 
countries like India.20. 
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Poisoning can be either acute or chronic based on their duration of 
exposure. Acute poisoning is a medical emergency which has been reported 
that it constitutes 10% of admissions in medical emergency departments in 
India21. Organophosphorus compounds (OP) are the most common 
pesticides which are being used in agriculture since late 1930s. The 
morbidity and mortality results from acute and chronic exposures of humans 
to OP pesticides have also become a major public health concern22. 
ORGANOPHOSPHOROUS COMPOUNDS 
‘Organophosphates’ (OP) is a generic term given for the organic 
derivatives of phosphorus. OP compounds are generally esters, amides or 
thiol derivatives of phosphoric acids with two organic group and additional 
side chain groups. They are used as insecticides, nematocides, fungicides or 
herbicides and plant growth regulators worldwide23. 
GENERAL STRUCTURE AND PHYSICAL PROPERTIES OPCs 
There are over 100 different OPCs produced for agricultural purposes. 
They usually differ in their physical, chemical and biological properties.  
OPCs are esters or thiols derived from phosphoric acid. They are slightly 
soluble in water. They have a high oil-water coefficient and low vapour 
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pressure. OPCs are lipophilic compounds and are degraded by hydrolysis 
yielding water soluble products24. 
The general structure of OP compound is shown in the Figure.1 
 
Fig.1: General Structure of Organophosphates25. 
The molecule of OP contains two lipophillic, aryl or alkyl groups (R1 
and R2) which are bonded to a phosphorus atom either directly forming 
phosphinates, or through an oxygen or sulfur atom to form 
phosphorothioates. It contains highly electronegative –X group which can be 
a halide, aliphatic, heterocyclic or aromatic and it is known as ‘leaving 
group’ since it is the group which is released upon hydrolysis. The toxicity 
level depends on the –X group25. 
PHARMACOKINETICS OF OPCs 
          The pharmacokinetic activities of OPCs have been studied in animal 
models showed that the cholinergic toxic effects are similar to human 
symptoms which suggest that the AChE inhibition is an important 
determinant of the acute toxicity of OP intoxication24,25. 
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1.       ABSORPTION AND DISTRIBUTION OF OPCs   
The OPCs are absorbed through skin, conjunctiva, oral mucosa, GIT, 
respiratory tract either by direct contact, ingestion, inhalation or injection26. 
Following absorption, the OPs are rapidly distributed in all tissues especially 
in liver, kidney, CNS and salivary glands and also in the fat stores. The 
lipophilic moiety of OP facilitates the absorption and redistribution. The 
elevated peak level is seen about 6 hours after absorption24. 
2. METABOLISM 
 The metabolism of OPCs occurs in the Liver by oxidation and 
hydrolysis which act on ‘thioates’ and ‘oxons’. The oxidation products have 
different degree of toxicity25. The phosphorothioates (P=S) of OPCs are 
oxidized by desulphuration mediated by Cytochrome (CYP) 450 isoforms to 
their active oxon form which is the primary toxin. The active oxon forms 
which inhibit AChE are spontaneously hydrolyzed within 0.7 hours to 31 
hours of exposure. The hydrolytic process is enhanced by hydrolases, such 
as the A-esterases, for example Paraoxonase116,26. 
3. EXCRETION  
The excretion mainly occurs via urine. A lesser quantity is eliminated 
through feces and exhaled air. The rate of excretion reaches its peak value 
within two days of intoxication and declines quickly26,27. 
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MECHANISM OF TOXICITY 
 The basic mechanism of toxicity by OPCs is associated with the 
inhibition of Acetylcholinesterase (AChE) which occurs in a stepwise 
manner. The initial step is the nucleophilic attack of the serine hydroxyl 
moiety at the active site of cholinesterase on phosphorus group of OPCs. It 
results in the formation of reversible enzyme- inhibitor complex and then the 
cleavage of OPCs occurs. It results in the formation of a covalent P-O bond 
and the phosphorylated enzyme. This phosphorylated enzyme cannot 
hydrolyze acetylcholine28,29. The time interval between the exposure of OP 
intoxication and the formation of irreversible phosphorylated enzyme 
complex is referred to as ‘aging’ which differs with respect to the type of 
OPCs29,30.  
ACUTE POISONING 
 Clinical effects of acute OPC exposure are divided into three types 
depend on the onset and duration of clinical manifestations22. 
a. Initial acute cholinergic syndrome (ACS) 
b. Intermediate syndrome (IMS) 
c. Delayed polyneuropathy (OPIDN) 
 
 CLINICAL MANIFESTATION
The clinical manifestation
symptoms occur within 30 min
exposure and the cholinesterase activity, the poisoning is classified as latent, 
mild, moderate and severe
poisoning is classified biochemically by using Namba
Serum Cholinesterase activity
 
 
 
 
 
 
 
 
 
Fig.2: Classification of OPC poisoning based 
on severity24. 
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ACUTE CHOLINERGIC SYNDROME (ACS) (TYPE I PARALYSIS)  
Acute Cholinergic crisis occurs within 48 hours of exposure5.The 
accumulation of ACh due to the inhibition of AChE causes the initial 
stimulation of cholinergic synapses. On the basis of receptor stimulation, the 
clinical manifestations are classified into muscarinic, nicotinic, and central 
nervous system (CNS) effects29. 
 
 
 
 
 
 
 
Table.1: Clinical manifestations of OPC poisoning according to the receptor 
type24. 
INTERMEDIATE SYNDROME (TYPE II PARALYSIS) 
 The term intermediate syndrome (IMS) was first described by 
Senanayake and karallidde (1987) since it occurred in the interval between 
cholinergic crisis and the onset of organophosphorus induced delayed 
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polyneuropathy (OPIDP)31. It occurs 24 to 96 hours after the ingestion of an 
OP compound. This syndrome generally occurs among patients with severe 
and prolonged inhibition of AChE. 
 The clinical features are muscle weakness predominantly proximal 
muscles and neck flexors. Recovery from this type of paralysis takes place in 
5 to 18 days unless it is complicated by infections and arrhythmias. The 
pathogenesis of intermediate syndrome is presumed to be due to dysfunction 
of neuromuscular junction and oxidative stress24. Although cholinergic crisis 
is the earliest manifestation, it is the intermediate syndrome which is 
responsible for the high mortality rate31. 
ORGANOPHOSPHATE INDUCED DELAYED NEUROPATHY 
(TYPE III PARALYSIS) 
Organophosphate-induced delayed neuropathy (OPIDN) occurs 
usually by 7 to 21days after exposure due to the inhibition of neuropathy 
target esterase (NTE) enzyme in nervous tissues and spinal cord by certain 
OPCs. The neuropathy is found to be occurring due to phosphorylation and 
aging of enzyme NTE6. The clinical manifestations are associated with early 
symptoms, paraesthaesias and calf pain and symmetrical motor axonopathy 
with mild sensory loss7. 
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DIAGNOSIS AND LABARATORY FINDINGS 
Initial diagnosis is made from the history of exposure and detailed 
clinical examination. Miosis is a strong clinical indicator of OPC 
poisoning29. 
The diagnosis of exposure to OPC is biochemically confirmed by the 
estimation of Cholinesterase activity. Clinical manifestations appears when 
the AChE activity is <50% of normal and BuChE is <70% of normal. Since 
BuChE is relatively more sensitive to inhibition and rapid to recover, it can 
be used in monitoring the disease progression and response to therapy8,24. 
Metabolites of OPCs in urine can be tested to confirm the exposure and to 
estimate the level of absorption of OPC from stomach. Although the direct 
measurement of OPC in blood on admission gives the level of severity of 
poisoning is practically difficult for routine use32. 
MANAGEMENT  
 OPC poisoning is a medical emergency and the patient has to be 
hospitalized in the ICU. The initial management of OPC poisoning is to 
ensure a secured airway and the decontamination of skin and stomach. 
Further therapeutic management is based on the history of intoxication, 
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clinical assessment and level of serum CHE activity which is used for 
monitoring32.  
SPECIFIC ANTIDOTE THERAPY 
 The antidote therapy includes muscarinic antagonist usually atropine, 
and oximes. Atropine is an anticholinergic drug33 whereas oximes are 
nucleophilic substances clinically used to reverse the activity of inhibited 
AChE before aging and are to be given as early as possible34.  Despite the 
reactivation of AChE, the use of oximes has little effect on the outcome of 
OPC poisoning. However the animal studies have shown that oximes are 
useful in reactivation of AChE with low level of serum OPC34. 
XENOBIOTIC METABOLISM 
 The biotransformation of foreign substances (Xenobiotics) by 
enzymatic pathways which occurs primarily in the liver is known as 
xenobiotic metabolism35. There are two metabolic pathways: Phase I and 
Phase II metabolism. The phase I metabolism consists of oxidation and 
hydrolysis by cytochrome P-450-dependent mixed-function oxidase system 
and esterases36. 
 Fig.3: Xenobiotics of Organophosphor
The inactive thio
phase I metabolism which consists of various 
especially CYP2B6 and CYP2C19 are involved
OPCs are then hydrolyzed by A
Paraoxonase1 (PON1) 
 Esterases are classified into A
upon the inhibition of the enzyme by Diethyl p
(E600)38,39. A-esterases are
sensitive to E600. Paraoxonases is
belongs to the group of B
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ous Compounds
-organophosphates are activated by the action of 
Cytochrome P450s (CYPs), 
37
. The active oxon forms of
-esterases especially the polymorphic
enzyme. 
SERUM ESTERASES 
-esterase and B-esterases depending 
-nitrophenyl phosphate
 not inhibited by E600 while B-
 a member of A-esterases. Cholinesterases 
-esterases40,41. 
 
 
 
 
 
esterases are 
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CHOLINESTERASE 
Cholinesterase (CHE) [EC 3.1.1.8], Acylcholine acylhydrolase 
contains a serine residue in the conserved region of –Gly-X-Ser-X-Gly motif 
at the active site of the enzyme42. It catalyzes the hydrolysis of ester of 
choline including acetylcholine (Ach). Cholinesterase is essential for the 
cholinergic neuron to return to its resting state after activation. It was first 
discovered and suggested by Dale in 1914 and was established by Loewi and 
Navratil in 192643. 
CHE has been found in many tissues including central nervous 
system, peripheral nervous system, plasma and RBCs. CHE is classified into 
two types, Acetyl cholinesterase [EC 3.1.1.7] and Butyrylcholinesterase [EC 
3.1.1.8] based on the ability of the enzyme to specifically hydrolyze the 
choline esters42,43. 
ACETYL CHOLINESTERASE [EC 3.1.1.7] AChE  
Acetylcholinesterase is also known as true cholinesterase, specific 
cholinesterase or acetylcholine acetylhydrolase. It hydrolyzes the cationic 
neurotransmitter acetylcholine into inactive metabolites choline and acetic 
acid at the post-synaptic nerve ending and terminates the signal 
transmission44. It is synthesized by hematopoiesis and present in conducting 
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tissues such as neuromuscular junctions, central and peripheral nervous 
tissues, motor and sensory fibers, cholinergic and non- cholinergic fibers and 
also in RBC cell membranes45. AChE is a highly specific catalytic enzyme 
which diffuses 25000 molecules of Ach per second and responsible for the 
diffusion-controlled reaction43. 
STRUCTURE 
The molecule of AChE is an ellipsoid with a homodimer containing 
531 amino acids. Each subunit is of 69kDa. It contains two subsites namely 
‘anionic’ and ‘esteratic’ corresponding to the catalytic and choline binding 
pocket respectively46. 
 
Fig.4: Active site of AChE 
Figure.4 explains the active site of AChE containing the two binding 
subsites viz, ‘esteratic’ and ‘anionic’sites. In addition to two subsites of 
active centre, AChE contains one or more peripheral anionic sites distinct 
from the choline-binding pocket of the active site. It acts as the binding site 
 for ACh and quaternary ligands
hydrolase and acts as a binding site for the choline molecule. The ‘anionic’ 
site interacts with the charged quaternary ammoniu
residue47. 
MECHANISM OF ACTION of AChE 
The anionic subsite of AChE is uncharged and 
mechanism of enzyme involves the electrostatic attraction between 
positively charged quaternary amine of choline moiety of Ach
The hydrolysis of acetylcholine is i
hydroxyl 200 in the esteratic subsite
Fig.5: shows the hydrolytic degradation of Ach into Choline and 
acetic acid.  
The enzyme binds to
leaves the free choline. Then, 
by a water molecule. It is assisted by histidine 440 and liberates acetic acid 
and finally the free enzyme is regenerated
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ISOFORMS OF AChE 
AChE exists in various oligomeric forms which are identical in 
catalytic properties, but differ in their quaternary structure and physical 
properties. It is encoded by a single gene located in the long arm of 
chromosome 7 (7q22). The variation in isoforms results from alternative 
mRNA processing and post translational modifications of catalytic and 
structural subunits49. 
BUTYRYLCHOLINESTERASE [EC.3.1.1.8] BuChE 
BuChE is also known as pseudo cholinesterase. It is an α- 
glycoprotein synthesized in the Liver and is found in blood plasma, smooth 
muscle, pancreas, adipocytes, skin, brain and heart. The normal value ranges 
from 5900-13,200 IU/L50. 
STRUCTURE 
 
Fig.6: Structure of active site of BuChE 
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The gene for BuChE is lies on the long arm of chromosome 3(3q26)51. 
It occurs as a tetrameric form and contains 574 amino acids with Mr of 
85kDa. The active site lies at serine 198 residue from the N- terminal52. 
MECHANISM OF ACTION  
The mechanism of action of BuChE resembles that of AChE. BuChE 
has three subsites at the active centre of the enzyme viz, peripheral anionic 
site (PAS) at the entrance of enzyme surface, narrow aromatic gorge leading 
halfway inside the enzyme and active site found at the bottom of aromatic 
gorge51.. 
INHIBITORS OF AChE AND BuChE 
The inhibitors of CHE are classified into two groups, Reversible and 
irreversible according to the mechanism of action. Carbomates are reversible 
whereas OP Compounds are Irreversible Inhibitors28,54. 
MECHANISM OF INHIBITION  
The inhibition of AChE by OPCs is associated with the nucleophilic 
attack of serine residue to the alkyl phosphorus group of OPCs29,54. 
Organophosphates strongly phosphorylate the cholinesterases. Unlike the 
acetylated enzyme the phosphorylated form of enzyme is highly stable and is 
incapable of regenerating the enzyme activity. Initially the phosphorylation 
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process is reversible and further enzymatic reaction makes irreversible 
AChE54. 
 
Fig.7: Mechanism of inhibition of OPCs. 
Figure.7 explains the nucleophilic attack of serine residue at the active 
site of the enzyme to the phosphorus of OPCs51.   
AGING OF CHOLINESTERASE  
The irreversible phosphorylation of enzyme forms a stable 
phosphorylated AChE. The time interval between the exposure of OPC 
intoxication and the formation of phosphorylated enzyme is known as 
‘aging’34,55. Once the aging process is achieved, the binding between OPC 
and serine moiety of active site is permanent. The aging process takes place 
at varied time intervals, depending upon the nature of the organophosphorus 
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compounds, for example dimethyl OP has half life of 3.7 hours after 
exposure while it is 33 hours in the case of diethyl OPCs56. 
COMPARISON OF AChE AND BuChE ACTIVITY 
Characteristics AChE BuChE 
Site Nerve synapse, 
Neuromuscular 
Junction, RBC 
memebrane 
Plasma, Liver, 
Kidney, Adipose 
tissue 
Structure Homo dimer Tetramer 
Active site 14 aromatic amino 
acids 
8 aromatic amino 
acids 
Substrates Acetylcholine Tributyrin, 
Tripropionin, 
Succinyl choline 
Half life 120 days 7- 12 days 
Clinical Features Appear when >50% of 
enzyme is reduced 
Appear when >70% 
of enzyme is reduced 
Inhibition/Regeneration  Relatively slow but 
strong inhibition by 
inhibitors 
Rapid inhibition and 
fast regeneration 
Biochemical 
importance-Analysis 
More Specific to 
confirm the exposure  
to inhibitors 
More sensitive. Used 
in monitoring the 
response to therapy   
 
Table.2: Comparison of AChE and BuChE53 
REACTIVATION OF CHOLINESTERASE  
The reactivation compounds of inhibited enzymes are cationic oximes 
formed from pyridine aldehydes which acts as a nucleophile. The 
mechanism of action of oximes involves the nucleophilic attack on 
phosphate group of OPC, thus forms a phosphorylated oxime and release the 
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enzyme activity before the process of aging56. Reactivation is effective when 
the oximes are given within one hour and the reactivation may vary with the 
type of OPCs used and the blood level of OPC34.   
PARAOXONASES 
 Paraoxonases are a group of enzymes belong to A-esterases. These 
enzymes act only catalytically and not stoichiometrically on their substrates 
where the active centre of the enzyme is not altered in their hydrolytic 
activity. The name “Paraoxonases” is derived from its commonly used in-
vitro substrate Paraoxon (formerly as E600) which is used for the analysis of 
its enzyme activity39,41. 
ISOENZYMES OF PARAOXONASES 
  Human Paraoxonase has three isoenzymes namely PON1, PON2, 
PON3 and the genes are located on the long arm of Chromosome 7q21.3-
22.1. It was found that PONs of mammalian species shared 60% and 70% of 
identity in their amino acid and nucleotide sequence respectively12. The 
isoenzymes differ in their tissue distribution, substrate specificity and degree 
of activity57,58. 
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STRUCTURAL CHARACTERIZATION AND TISSUE 
DISTRIBUTION 
 PON1 is synthesized in the liver and secreted into the blood in 
association with High density lipoprotein (HDL) bound to Apo-A1. 
However HDL and ApoA1 concentrations are not related to the genotypes 
and activity of PON159. Serum PON1is a heterodimer with 354 amino acid 
residues and the molar mass (Mr) of each subunits are 39kDa and 42kDa60.  
PON1 is dependent on Calcium ions for its maximum enzyme activity which 
can also be stimulated in-vitro by the addition of 1M sodium chloride61,62. 
 PON2 is present in almost all tissues as a constitutive enzyme in 
humans with highest expression in liver, lung, heart and placenta. It is a 
homodimer with the Mr of 39kDa12,60. PON3 is synthesized primarily in the 
liver. It is also an HDL associated protein like PON1 with molecular mass of 
40kDa. 
ENZYMATIC ACTIVITIES OF PARAOXONASES 
 The isoenzymes of PONs are basically lactone hydrolases or 
lactonases [EC 3.1.8.1] with overlapping substrate specificities that 
hydrolyze lactones which are the oxidative products of arachidonic acid, 
docosahexaenoic acid, homoserine, homocyteine 12,59,60. 
An N-acyl-L-homoserine lactone + H2O N-acyl-L-homoserine + lactone   
23 
 
 They have two more allozymes activities such as arylesterase and 
paraoxonase that are governed and controlled by the presence of two alleles 
at same autosomal locus responsible for the polymorphism which affects the 
degree of enzyme activity58,60. 
 Arylesterase [EC 3.1.1.2] activity is present in all PONs by which 
they metabolize the oxidative products of Low density Lipoprotein (LDL) 
and aromatic carboxylic acid esters with variable degree of activity. PON3 
has limited arylesterase activity60. The reaction is written as 
Aromatic carboxylic acid ester + H2O an aromatic alcohol +                  
         carboxylic acid 
PON1 is the only isoenzyme which has maximum paraoxonase      
[EC 3.1.1.81] activity that hydrolyzes a variety of OPCs12,57,59,60. PON3 has 
very low paraoxonase activity and PON2 does not have the following 
activity. 
An aryl dialkyl phosphate +H2O  an aryl alcohol + dialkyl phosphate 
 The bulky drugs like spironolactone and lipid lowering drug lovastatin 
are hydrolyzed only by PON3 by its lactonase activity12,60. 
PHYSIOLOGICAL ROLE OF PONs 
 Paraoxonase 1 and 2 mediate the enzymatic protection for all tissues 
(anti oxidant) mainly by preventing the endothelial damage to vascular 
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system caused by oxidative stress. They prevent Low density lipoprotein 
(LDL) lipid peroxidation and reverse the oxidation of minimally modified 
LDL (MM-LDL) and also inhibit the ability of oxidized LDL to induce 
monocyte chemotaxis and thereby the consequent series of events leading to 
atheroma formation60.  
 PON2 has high lactonase activity towards Acyl homoserine lactones 
(AHL) which is produced by the quorum sensing bacterial species for the 
regulation and expression of their virulence genes. PON2 inactivates the 
AHL either by cleaving the ester bond or opening the lactone ring and 
disturbs the quorum sensing in pathogenic bacteria. Studies have shown that 
PON 2 expression was up regulated during infectious process and this aided 
the monocyte maturation to macrophages59 that explained its role in innate 
immune response.   
  PON1 has an exclusive action in Xenobiotics for the 
detoxification of OPCs15. The clinical studies carried out so far on 
Paraoxonases revealed that any changes at the genetic level of PONs have 
effect on their enzymatic activity.  
POLYMORPHISM OF PARAOXONASES 
 PON1 has more than 160 genetic polymorphisms, among which the 
two polymorphism in the coding region and five in the promoter region have 
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been studied extensively10,12. Promoter region polymorphism contributes to 
the variations in the expression and concentration of the enzyme63. The 
Leucine to Methionine polymorphism at coding region 55 (L55M) is 
associated with the variability in enzyme levels. The PON1 coding region 
Q192R (Glutamine/ Arginine) polymorphism has been widely investigated 
for its protective role in OPC toxicity and cardio vascular disease 
(CVD)10,12,63. 
PON2 has a clinically significant polymorphism at the codon 311 
(Cysteine/Serine) which are associated with Coronary heart disease 
(CHD)59,64. Polymorphism of PON3 is the least studied compared to PON1 
and PON264. The frequency of all the polymorphic forms of PONs varies 
considerably in different races. 
PARAOXONASE 1 (PON1) 
 Paraoxonase1, aryl dialkylphosphatase [EC 3.1.8.1] is a member of 
Paraoxonase hydrolase family which belongs to ‘A-esterase’ type of serum 
esterases65. Human PON1 is a glycosylated protein.  
 Hassett., et al (1991) explained that the hydrophobic leader sequence 
of the mature protein is retained from which only the starting amino acid 
methionine is cleaved. Sorenson., et al (1999) described that the retained N-
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terminal signal peptide is the required structure for the association of PON1 
with HDL. It was reported that PON1 has two Ca2+ binding sites needed for 
its stability and activity59. PON1 has histidine and tryptophan residues at its 
active site66. The 3D structure of PON1 enzyme has been described by  
Harel M., et al and it is a 6-bladed beta-propeller with a unique active-site 
lid which is also involved in binding to HDL67.   
 
 Fig.8: Cartoon image of the structure of rPON1 variant G2E6. The 
calcium ions are denoted as green balls at the center; phosphate ion as red 
stick model, reproduced from the work of Harel M., et al (2007).  
 Animal studies done by Lourdes Rodrigo., et al showed that 
Paraoxonase antigen is present in the endothelial cells of all tissues, in the 
centrilobular region of hepatocytes and within the endothelial cells of 
capillaries and arteriolar branches of hepatic artery. Paraoxonase1 is present 
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in the microsomes of a cell along with the line of CYP450 of xenobiotic 
system of the Liver66.  
Paraoxonase1 is basically a lactonase which also has two different 
allozyme activities namely paraoxonase and arylesterase due to the presence 
of two alleles at one autosomal locus which appears to be inherited as a 
simple dominant mendelian trait61. Paraoxonase activity is stimulated by 
high concentration of Sodium Chloride (1M). Both enzymes are dependent 
on calcium ions for their effective activity62. Serum PON1 activity is widely 
variable globally.  
The catalytic mechanism of serum PON1 has been elucidated by 
Harel M., et al (2007) by determining its catalytic pH-rate profile. It has 
been shown that there is production of hydroxide ion by deprotonation of 
water molecule by the His-His dyad and calcium complex present at the 
active site of the enzyme without changing its structure stoichiometrically. 
This hydroxide anion attacks the carbonyl ester bond of the substrate to form 
an intermediate which is broken down into water soluble products and left 
the enzyme free67. 
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Fig.9: The postulated catalytic site of PON1 
Figure.9 shows the postulated catalytic site of PON1 where the upper 
calcium atom (Ca-1) as green ball, the phosphate ion at the bottom of the 
active site, and the postulated His-His dyad, reproduced from the work of 
Harel M, et al (2007).  
Catalysis occurs by the attack of ester bond by the hydroxide anion. 
This anion is formed by deprotonation of water molecule by His dyad in the 
presence of calcium and phosphate ions at the active centre.  
 
Fig.10: The postulated mechanism of action of Serum PON1, 
reproduced from the article of Harel M, et al (2007) 
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Serum PON1 degrades the toxic active forms of a variety of OPCs by 
its paraoxonase activity by which it plays a clinically significant role in OPC 
poisoning. It reduces the oxidative stress by reducing the peroxidation of 
membrane phospholipids caused by toxic substances. It was postulated that 
the protectivity and susceptibility to OPC toxicity is influenced by the level 
of activity15. The level of activity of the allozymes is affected mainly by the 
polymorphism of PON1 at the coding region192 where Glutamine is 
replaced by Arginine.  
It was shown that paraoxonase activity is highly variable than 
arylesterase activity in Q192 R polymorphism and their ratio which clearly 
discriminates the enzyme activity into three types that exists as three 
phenotypes namely AA, AB, BB that has low, moderate and high level of 
activity respectively which affects the level of OPC in blood61. It was 
identified that these phenotypes are genetically determined as QQ, QR, RR 
of PON1 due to polymorphism at Q192R61,68. It was also found that though 
the frequency of phenotypes is widely variable worldwide, it is not 
significantly different in both gender and age groups. 
Experimental studies on knockout mice of PON1 have shown that the 
susceptibility to OPC toxicity and atherosclerosis was increased in mice 
which was totally lacking of PON169.  It was shown in animal studies that 
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PON1 level was up regulated in adult mice after exposure to OPC70 which 
has been evidenced by immunostaining by Harel M, et al (2007). Animal 
studies postulated that therapy with PON1 may prove beneficial in OPC 
poisoning by its metabolic capacity in lowering the concentration of OPC in 
blood and tissues71. 
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RATIONALE FOR THE STUDY 
Acute OPC poisoning is a medical emergency. It has been reported 
that approximately 10% of admissions in intensive medical care department 
in India accounts for acute OPC poisoning21.  
Early diagnosis and assessment of severity of poisoning is crucial in 
saving lives. Direct measurement of OPC in blood and its metabolites in 
urine is practically difficult as a routine procedure. Estimation of AChE is 
used to confirm the exposure of OPC. Although serum Cholinesterase 
activity has a significant role in monitoring the progression of disease and 
response to therapy, it could not predict the level of OPC in blood and extent 
of toxicity34.  
The reinhibition of CHE occurs with high level of OPC even with the 
high dose of oxime therapy. The reason for this failure of response to oxime 
therapy is the high concentration of OPC in the blood and tissues71. 
Paraoxonase1 (PON1) is a xenobiotic enzyme that degrades the active OPC 
and reduces the oxidative stress which is one of a cause for the intermediate 
syndrome thereby has a protective role in OPC poisoning13,14. Since 
Paraoxonase1 is a polymorphic enzyme, its phenotypes differ in their level 
of enzyme activity will affect the level of OPC in blood and tissues12 and the 
severity of disease. 
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We therefore proposed to study and evaluate the relationship between 
the enzyme Cholinesterase that is inhibited by OPCs and the enzyme 
Paraoxonase1 that detoxifies the OPCs in ‘Acute’ OPC poisoning with the 
following objectives.  
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AIM 
To identify the serum Paraoxonase1 (PON1) phenotype and its 
relationship with serum Cholinesterase activity in patients with acute 
Organophosphorous compound (OPC) poisoning. 
OBJECTIVES 
1. To determine the phenotype of serum Paraoxonase1 (PON1) by using 
the ratio of the allozymes Paraoxonase and Arylesterase activities of 
serum Paraoxonase1enzyme. 
2. To estimate the serum Cholinesterase enzyme activity. 
3. To assess the correlation between the phenotypic enzyme activity of 
serum Paraoxonase1 and serum Cholinesterase activity in acute OPC 
poisoning. 
4. To establish the need for identification of serum Paraoxonase1 
phenotype in patients with acute OPC poisoning for the early 
detection of their susceptibility to OPC toxicity. 
5.  To emphasize the significance of Serum PON1phenotyping for the 
extended medical management and follow up of those patients with 
susceptible phenotype so as to ensure a better prognosis. 
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MATERIALS AND METHODS 
STUDY DESIGN 
The study design is an experimental analytical observational 
correlation between two variables in acute OPC poisoning. 
STUDY CENTRE 
1. Department of Biochemistry, Govt. Stanley Medical College 
and Hospital, Chennai. 
2. 24 hours Clinical Biochemistry - Central Laboratory, Govt. 
Stanley Hospital, Chennai. 
3. Intensive Medical Care Unit (IMCU), Govt. Stanley Hospital,  
Chennai. 
STUDY DURATION 
Six months 
STUDY POPULATION 
 Patients with acute OPC poisoning, admitted in Intensive Care Unit, 
Govt. Stanley Hospital, Chennai. 
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CRITERIA FOR SELECTION 
Inclusion criteria 
 
1. Patients who are exposed to Organophosphorous compound 
(OPC) and have been admitted within 24 hours of exposure. 
2. Patients who are willing to participate in the study with 
informed consent. 
3. Age: 18-65 years of age 
4. Both genders 
Exclusion criteria 
1. Patients who have long standing co-morbid medical illnesses 
like chronic liver diseases, Diabetes mellitus. 
2. Patients who are exposed to other poisons along with OPC. 
 SAMPLE SIZE      
 54 Patients with Acute OPC poisoning 
STUDY PROCEDURE 
The study was conducted at the Department of Biochemistry, 
Govt.Stanley Medical College, Chennai and in the 24 hours Clinical 
Biochemistry Laboratory, Govt. Stanley Hospital, Chennai. The sources of 
data were collected from the Intensive Medical Care Unit (IMCU), 
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Govt.Stanley Hospital, Chennai. The study was commenced with the 
approval obtained from the Institutional Ethics Committee, Govt. Stanley 
Medical College, Chennai. 
ETHICAL CONSIDERATIONS AND RECRUITMENT OF STUDY 
POPULATION 
All the Patients who were exposed to Organophosphorous compounds 
had been admitted within 24 hours of exposure were informed about the 
study purpose without interfering with their routine management. Only those 
patients who agreed to participate in the study were recruited. Informed 
consent was obtained from all the patients who participated in this study. All 
the procedures, potential risks and benefits related to the study were fully 
explained in their mother tongue. All their queries were answered to their 
satisfaction. 
CLINICAL ASSESSMENT 
A detailed history about OPC exposure and comorbid medical illness 
was taken and a complete clinical examination was done for the patients 
who participated in the study. The socio-demographic details along with 
their contact numbers were noted in the clinical assessment Proforma.  
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SAMPLE COLLECTION 
5 ml of venous blood from Antecubital vein was collected under strict 
aseptic conditions from patients who fulfilled all the inclusion criteria. 2ml 
of blood was taken in Potassium oxalate, Sodium Fluoride vacutainer and 
the remaining 3ml in a plain vacutainer. Samples for measuring serial 
estimation of serum Cholinesterase activity were collected on Day 1, 3 and 5 
of admission. 
SAMPLE PROCESSING AND STORAGE 
 Samples for plasma were centrifuged within 20 minutes of           
collection at 2500 rpm for 10 minutes. Samples for serum were centrifuged 
after clot retraction at 2000 rpm for 15 minutes. Plasma and Serum were 
collected as two aliquots of 500µl. The samples were analyzed immediately 
for the following parameters. 
ANALYTES 
1. Serum Total Protein.         
2. Random Plasma Glucose.  
Samples containing values within the normal range were analyzed for the 
following enzyme activity. 
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ENZYME ACTIVITY 
1. Serum Cholinesterase activity 
2. Serum Paraoxonase activity of PON1      
3. Serum Arylesterase activity of PON1 
The serum CHE activity was measured in day 1, 3 and 5 samples and the 
average value was taken for statistical analysis. Remaining samples were 
stored at -20oC to assess inter-assay variability. 
COLLECTION AND PROCESSING OF QUALITY CONTROL SERA 
 200µl of serum was obtained from the blood collected from each 
healthy individual who attended the Master health check up at 24 hours 
Clinical Biochemistry Laboratory, Govt. Stanley hospital, Chennai and 
mixed well to obtain the 10ml of Quality Control (QC) Sera. 
 15% of Ethylene Glycol was added as a preservative to the Quality 
Control (QC) Sera and stored as 40 aliquots of 250 µl at -20oC. All the three 
enzymatic activities mentioned above were analyzed before and after the 
addition of preservative to identify the effect of Ethylene glycol. 
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SAMPLE ANALYSIS 
ESTIMATION OF SERUM TOTAL PROTEIN 
Method 
 Biuret Method 
Principle 
 The Cupric ions (Cu2+) of Biuret reagent form purple coloured 
multivalent complexes quantitatively with peptide bonds of proteins under 
strong alkaline medium. The intensity of the purple colour is directly 
proportional to the concentration of serum total protein72. 
Reference range 
 Adults: 6.5 – 8.5 g/dL72 
Criteria for inclusion in the study 
 Only patients who had total serum proteins above 6.5g/dL were 
included. 
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ESTIMATION OF RANDOM PLASMA GLUCOSE 
Method 
 Trinder’s method (Commercial Reagent Kit) 
 Principle 
 Glucose is oxidized to Gluconic acid and hydrogen peroxide by 
Glucose oxidase (GOD). The peroxidase (POD) enzyme catalyzes the 
oxidative coupling of 4-aminoantipyrine (4-AAP) with phenol to yield a   
coloured complex quinoneimine and its absorbance is directly proportional 
to the concentration of plasma glucose of the sample72. 
 
Glucose + O2 + H2O                   Gluconic acid + H2O2 
H2O2 + Phenol + 4-AAP                    Quinoneimine dye + 2H2O 
Reference range 
 Adult (Fasting): 74 – 100 mg/dL72 
 Random Plasma Glucose: <200 (ADA Criteria) 
Criteria to include in the study 
  Only patients with Random Plasma Glucose level below 200mg/dl 
were included in the study.  
GOD 
 POD 
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MEASUREMENT OF SERUM CHOLINESTERASE ACTIVITY 
Method 
Kinetic method as per the recommendation of DGKC (Commercial 
Reagent Kit)  
 Principle 
 Serum Cholinesterase (CHE) catalyzes the hydrolysis of 
butyrylthiocholine present in the reagent to form butyrate and thiocholine. 
Thiocholine reduces the yellow coloured hexacyanoferrate III to colourless 
hexacyanoferrate II. The change in absorbance is directly proportional to the       
activity of serum cholinesterase in the sample72. 
 
    Butyrylthiocholine + H2O                   Thiocholine + Butyrate 
 
Thiocholine + Hexacyanoferrate III                    Hexacyanoferrate II 
Reagent Composition 
1. Reagent 1 
Active Ingredients Concentration 
Hexacyanoferrate III 2 mmol/L 
Pyrophosphate Buffer (pH 7.6) 75 mmol/L 
CHE 
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2. Reagent 2 
Active Ingredients Concentration 
Butyrylthiocholine 15 mmol/L 
 
Working Reagent preparation 
 4 parts of Reagent1 with 1 part of Reagent2 were mixed to prepare the   
working reagent which was stable for 3hours at 15 – 25oC.  
Procedure 
 Analysis was done in a semi-auto analyzer after Quality control 
analysis with the preserved QC sera. Linearity of the reaction was checked 
for 5minutes in kinetic mode. Levey Jenning’s chart was plotted to monitor 
the performance of the test on a daily basis. To 1000µl of working reagent, 
50µl of serum sample was added. Reagent and sample were mixed well and 
incubated for 30 seconds at 37oC. The Change in absorbance per 30 seconds 
for the total measuring time of 90 seconds was measured at 405nm.  
Assay Parameters 
 Mode of reaction  - Kinetic mode 
Slope of reaction  - Decreasing 
 Wavelength   - 405 nm 
Temperature  - 37oC 
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Kinetic Factor  - 22653 
Blank    - Distilled Water 
Delay/ Lag time  - 30 seconds 
No of readings  - 3 
Interval    - 30 seconds 
Reagent volume  - 1000 µl 
 Sample volume  - 50µl 
Calculation 
Serum Cholinesterase Activity, U/ L   =  Abs/ minute X Factor 
Where,      Abs/ minute - Change in Absorbance per minute 
                                                 Factor = 22653 
Reference range72 
 Adult Females : 3930 – 10800 U/L  
Adult Males   : 4620 – 11500 U/L 
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MEASUREMENT OF SERUM PARAOXONASE ACTIVITY OF 
PON1 
Method 
Eckerson., et al method12,13. 
 Principle 
 Serum Paraoxonase1 hydrolyzes the pale yellow coloured substrate 
Paraoxon [o,o diethyl o- (4 –nitrophenyl phosphate)] into 4- nitrophenol and 
diethyl phosphate in the presence of a divalent cation ca2+  by its 
Paraoxonase activity. The increase in the intensity of yellow colour due to 
the formation of 4-nitrophenol is directly related to the enzyme activity 
which is stimulated by high concentration Sodium Chloride. 
 
Paraoxon + H2O                                   4- nitrophenol + Diethylphosphate 
 
Chemicals 
 All the chemicals are reagent grade in purity. 
1. Paraoxon  
2. Tris (hydroxyl methyl) amino methane 
3. Calcium chloride dihydrate 
PON1 
 Ca2+/ NaCl 
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4. Sodium Chloride 
5. Concentrated Hydrochloric acid 
Reagent Composition 
1. Reagent 1 
Active Ingredients Concentration 
Tris- HCl Buffer (pH 8.0) 50 mmol/L 
Calcium Chloride 0.9 mmol/L 
Sodium Chloride 1 mol/L 
 
2. Reagent 2 
Active Ingredients Concentration 
Paraoxon- ethyl PESTANAL 2 mmol/L 
 
Reagent preparation 
1. Tris Base stock: 0.5 mol/L 
 6.057g of Tris (hydroxyl methyl) amino methane was dissolved in 
80ml of distilled water and made up to 100ml which was stored in a 
polyethylene bottle at room temperature. 
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2. Preparation of 3N HCl: 3mol/L 
 25ml of Concentrated Hydrochloric acid (12N HCl) was dissolved 
with 60ml of distilled water and made into a final volume of 100ml with 
distilled water and stored at room temperature.   
3. Tris – HCl Buffer: 50mmol/L, pH 8.0 
 10ml of Tris Base stock was dissolved in 60ml of distilled water. pH 
was adjusted to 8.0 with 3N HCl after calibration of pH meter with pH 7 
standard solution . It was made into 100ml by adding distilled water with 
final pH adjustment of 8.0 ± 0.01. Solution was stored at 2-8oC. 
4. Preparation of Reagent 1: pH 8.0 
 13.23mg of Calcium chloride dehydrate was dissolved in 50ml of 
Tris-HCl buffer and mixed well until the solution become clear. 30 ml of the 
buffer was mixed. 5.844g of Sodium chloride was added and made into 
dissolve completely. pH was adjusted to 8.0 with 3N HCl. The solution was 
made into the final volume of 100ml with Tris-HCl buffer to obtain 
0.9mmol/L of CaCl2 and 1mol/L of NaCl. Stored at 2-8oC in polyethylene 
bottle. 
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5. Preparation of Working Reagent (R1 + R2) 
 Working reagent was prepared freshly prior to analysis. The density 
of purchased Paraoxon –ethyl PESTANAL (Paraoxon) is 1.274g/ml 
(4.6mol/L) at 25oC. 21.6 µl of Reagent 2 was dissolved which is equivalent 
to 27.52mg of substrate Paraoxon in 40ml of Reagent1 and mixed well. The 
solution was made into 50ml with Reagent1 to obtain 2 mmol/L of substrate 
concentration.  
6. Sample preparation (1 in 4 dilutions) 
 50 µl of sample was diluted with 200 µl with Reagent1. Dilution 
factor was 4. 
Standardization of the Procedure 
 Standardization of the procedure was done with the Quality Control 
sera in Dual beam Spectrophotometer. 
1.  Estimation of Non Enzymatic hydrolysis of the substrate 
 Non Enzymatic spontaneous hydrolysis of the substrate Paraoxon 
was measured by adding the substrate to Reagent1 in kinetic mode at 405 
nm for 15 minutes. Reagent blank was done to tare the effect of spontaneous 
hydrolysis of Paraoxon during analysis. 
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2. Linearity of the reaction 
 To 2800 µl of working reagent, 80 µl of the diluted QC sera was 
added and mixed well for 30 seconds. The proportion of increase in 
absorbance was noted from 30 seconds to 15 minutes by analyzing the 
kinetic mode at 405 nm.  Delay time and reading time were set according to 
the linearity of the reaction. 
3. Accuracy and Precision of the procedure 
 The Accuracy and Precision of the procedure were analyzed by 
measuring the enzyme activities using QC sera with the standardized general 
assay parameters and plotting the values in the Quality control chart. 
Assay Procedure 
 Analysis was started with blanking of the working reagent and 
monitoring the QC value. 80 µl of diluted serum sample was added and 
mixed well with 2800 µl of working reagent. Measurement was taken at 405 
nm. The change in absorbance is directly proportional to the Salt stimulated 
enzyme activity. 
Assay Parameters 
 Mode of reaction  - Kinetic 
Slope of reaction  - Increasing 
 Wavelength   - 405 nm 
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Temperature  - 25oC 
Kinetic Factor  - 7873 
Blank    - R1 + R2  
Delay/ Lag time  - 60 seconds 
No of readings  - 4 
Interval    - 60 seconds 
Read time   - 240 seconds 
Reagent volume  - 2800 µl 
 Sample volume  - 80µl 
 Dilution factor  - 4 
 Unit    - U/L 
Calculation 
 One unit of enzyme activity is equal to the formation of 1 
nmol/min/ml of the product 4-nitrophenol at pH 8.0 which is equivalent to 1 
µmol/min/L (U/L)73. 
Serum Paraoxonase Activity of PON1, U/ L =          Abs/min X TV X DF 
(Salt stimulated enzyme activity)                  ∑µmol X SV X Path length       
                  
                                                                         =       Abs/min x Kinetic Factor  
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Where 
        Abs/ minute    - Change in Absorbance per minute 
  TV (Total Reaction Volume) - 2880 µl 
  SV (Sample volume)  - 80 µl 
  DF (Dilution Factor)  - 4 
  Path length         - 1 cm 
  ∑µmol (Micromolar absorptive of 4-nitrophenol at pH 8.0 at 405 nm) 
     - 18.29 x 10-3  L µmol-1 cm-1 
Derived Kinetic Factor  - 7873  
MEASUREMENT OF SERUM ARYLESTERASE ACTIVITY OF 
PON1 
Method 
Modified Zeller’s method12,13. 
 Principle 
 Serum Paraoxonase1 is a Calcium dependent enzyme that catalyzes 
the hydrolysis of the colourless substrate Phenylacetate to form phenol and 
acetic acid by its Arylesterase activity. The change in absorbance due to the 
formation of phenol is directly proportional to the enzyme activity.  
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Phenylacetate + H2O                                 phenol + acetic acid 
Chemicals 
 All the chemicals are reagent grade in purity. 
1. Phenylacetate  
2. Tris (hydroxyl methyl) amino methane 
3. Calcium chloride dihydrate 
4. Concentrated Hydrochloric acid 
Reagent Composition 
1. Reagent 1 
Active Ingredients Concentration 
Tris- HCl Buffer (pH 8.0) 20 mmol/L 
Calcium Chloride 1 mmol/L 
 
2. Reagent 2 
Active Ingredients Concentration 
Phenylacetate 4 mmol/L 
 
 
 
PON1 
  Ca2+ 
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Reagent preparation 
1. Tris Base stock: 0.2 mol/L 
 2.423g of Tris (hydroxyl methyl) amino methane was dissolved in 
80ml of distilled water and made into a final volume of 100ml and stored in 
a polyethylene bottle at room temperature. 
 
2. Preparation of 3N HCl: 3mol/L 
  25ml of Concentrated Hydrochloric acid (12N HCl) was dissolved 
with 60ml of distilled water and made it into a final volume of 100ml with 
distilled water and stored at room temperature.   
3. Tris – HCl Buffer: 20mmol/L, pH 8.0 
 10ml of Tris Base stock was dissolved with 60ml of distilled water.  
pH was adjusted to 8.0 with 3N HCl. It was made into 100ml by adding 
distilled water with final pH adjustment of 8.0 ± 0.01 and stored at 2-8oC. 
4. Preparation of Reagent 1: pH 8.0 
 14.7 mg of Calcium chloride dihydrate was dissolved in 70ml of Tris-
HCl buffer and mixed well until the solution become clear. pH was adjusted 
to 8.0 with 3N HCl. The solution was made to the final volume of 100ml 
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with Tris-HCl buffer to obtain 1mmol/L of CaCl2 and stored at 2-8oC in 
polyethylene bottle. 
5. Preparation of Working Reagent (R1 + R2) 
 Working reagent was freshly prepared prior to analysis. The density 
of purchased Phenylacetate is 1.073 g/ml (0.79mol/L) at 25oC.  25.4 µl of 
Reagent 2 which is equivalent to 27.23mg of substrate Phenylacetate was 
dissolved in 40ml of Reagent1and mixed well. The solution was made into 
50ml with Reagent1 to obtain 4mmol/L of substrate concentration.  
6. Sample preparation (1 in 4 dilution) 
50 µl of Sample was diluted to 200 µl with Reagent1. Dilution factor 
was 4. 
Standardization of the Procedure 
 Standardization of the procedure was done with the Quality Control 
sera in Dual beam Spectrophotometer. 
1. Estimation of Non Enzymatic hydrolysis of the substrate 
 Non Enzymatic spontaneous hydrolysis of the substrate Phenylacetate 
was measured by adding the substrate to Reagent1 in kinetic mode at 270nm 
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for 10 minutes. Reagent blank was done to blank the effect of spontaneous 
hydrolysis of Phenylacetate during analysis. 
2. Linearity of the reaction 
 To 2980 µl of working reagent, 20 µl of the diluted QC sera was 
added and mixed well for 30 seconds. The proportion of increasing in 
absorbance was noted from 30 seconds to 10 minutes by analyzing the 
reaction in kinetic mode at 270nm. Delay time and reading time were set 
according to the linearity of the reactions. 
3. Accuracy and Precision of the procedure 
 The Accuracy and Precision of the procedure were analyzed by 
measuring the enzyme activities using QC sera with the standardized general 
assay parameters and plotting the values in the Quality control chart. 
Procedure for analysis 
 Analysis was started with blanking of the working reagent and 
monitoring the QC value. 20 µl of diluted serum sample was added and 
mixed well with    2980 µl of working reagent. Measurement was taken at 
270 nm. The change in absorbance is directly proportional to the enzyme 
activity. 
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Assay Parameters 
 Mode of reaction  - Kinetic 
Slope of reaction  - Increasing 
 Wavelength   - 270 nm 
Temperature  - 25oC 
Kinetic Factor  - 458 
Blank    - R1 + R2  
Delay/ Lag time  - 20 seconds 
No of readings  - 2 
Interval    - 60 seconds 
Read time   - 120 seconds 
Reagent volume  - 2980 µl 
 Sample volume  - 20µl 
 Dilution factor  - 4 
 Unit    - kU/L 
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Calculation 
 One unit of enzyme activity is equal to the hydrolysis of 1 
µmol/min/ml of the substrate Phenylacetate at pH 8.0 which is equivalent to 
1000 µmol/min/L of enzyme activity. The unit of serum Arylesterase 
activity is expressed in kU/L73. 
Serum Arylesterase Activity of PON1, kU/ L =           Abs/min X TV X DF 
               1000 X ∑µmol  X  SV X PL       
                 =      Abs/min X Kinetic Factor  
 
Where,  
     Abs/ minute    - Change in Absorbance per minute 
  TV (Total Reaction Volume) - 3000 µl 
  SV (Sample volume)  - 20 µl 
  DF (Dilution Factor)  - 4 
  PL (Path length)        - 1 cm 
 
 ∑µmol (Micromolar absorptive of phenol at pH 8.0 at 270 nm) 
     - 1310 x 10-6  L µmol-1 cm-1 
Calculated Kinetic Factor - 458     
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QUALITY CONTROL MANAGEMENT 
 The quality of the test procedures for analyzing the enzyme activities 
was monitored by doing Quality control sera analysis on daily basis. 
 The Mean and standard deviation (SD) values for plotting Levey 
Jenning’s Chart (Quality Control Chart) were calculated by measuring the 
enzyme activities of the QC sera for 20 days with the standardized general 
assay parameters in Dual Beam Spectrophotometer. The reliability and 
repeatability of the test procedures were evaluated from the QC chart using 
Westgard rules for Quality Control Management. Analysis was preceded if 
the QC values are within ± 2 SD.  
The intra assay variability of serum PON1allozyme activities was 
assessed by measuring them with same aliquots of QC sera and patients 
samples. The inter-assay variability of serum PON1allozyme activities was 
assessed by measuring the enzyme activity with parallel aliquots of same 
samples after one and two weeks from the first measurement. 
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DETERMINATION OF SERUM PARAOXONASE1 PHENOTYPE 
The phenotypes of serum PON1 of OPC poisoning patients were 
determined from their allozyme activities such as Paraoxonase and 
Arylesterase activities. It was derived by calculating the ratio of serum 
Paraoxonase and serum Arylesterase activities12. 
Phenotype of serum Paraoxonase1   =   Serum Paraoxonase activity 
 Serum Arylesterase activity 
REFERENCE RANGE FOR PHENOTYPIC CLASSIFICATION OF      
SERUM PON 168 
 
 
 
 
Phenotype of serum 
Paraoxonase1 
Ratio of PON 1 
allozymes activity 
Grades of Serum PON 1 
Activity 
AA < 3.0 Low 
AB 3.0 – 6.9 Moderate 
BB >6.9 High 
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STATISTICAL ANALYSIS AND RESULTS 
Socio demographic and biochemical data of 54 patients with acute 
OPC poising were set for statistical analysis. The Statistical analysis was 
performed using Statistical software SPSS (version 16) package.  
The biochemical values obtained from standardization procedures 
were expressed as mean, standard deviation and coefficient of variation. The 
enzymatic activities of Quality Control (QC) sera were presented as Levey 
Jennings chart. Distribution of socio demographic data and analytical 
variables used to screen the co-morbid medical illnesses were calculated by 
frequency analysis. The level and degree of association between two 
dependent variables were assessed by Pearson Coefficient of correlation. 
The comparison of mean values of variables among more than two 
independent groups was analyzed by ‘one way ANOVA’ test.  
The level and strength of correlation between serum paraoxonase1 
phenotypes and serum Cholinesterase activity was calculated using ‘Pearson 
coefficient of correlation’. A p value ≤0.05 was considered as statistically 
significant. The results of statistical analysis are presented as tables and 
charts. The socio demographic and biochemical data are attached in 
Annexure III. 
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Table.3: STANDARDISATION OF THE TEST PROCEDURES 
Table.3.1: NONENZYMATIC HYDROLYSIS OF THE SUBSTRATE 
Substrate Mean Standard Deviation 
Paraoxon (U/L) 3.1 ±0.65 
Phenylacetate 
(kU/L) 
0.26 ±0.09 
Table.3.1 shows the mean values of Non enzymatic hydrolysis of Paraoxon 
and Phenylacetate.  
Table3.2: VARIABILITY IN ENZYME ACTIVITY 
Table 3.2a: INTRA ASSAY VARIABILITY 
Measures Serum Paraoxonase 
activity (U/L) 
Serum Arylesterase 
activity (kU/L) 
Mean 294.34 72.14 
Standard Deviation ±7.82 ±1.52 
CV (%) 2.66 2.11 
Table.3.2a represents the intra assay variability in Serum Paraoxonase and 
Arylesterase activities of serum PON1. The Coefficient Variation (CV) for 
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serum Paraoxonase and Arylesterase activities are 2.66% and 2.11% 
respectively.  
Table.3.2b: INTER ASSAY VARIABILITY 
Measures Serum Paraoxonase 
activity (U/L) 
Serum Arylesterase 
activity (kU/L) 
Mean 287.24 71.29 
Standard Deviation ±9.36 ±1.96 
CV (%) 3.26 2.75 
  
 Table.3.2b represents the inter assay variability in Serum Paraoxonase 
and Arylesterase activities of serum PON1. The Coefficient Variation (CV) 
for serum Paraoxonase and Arylesterase activities are 3.26% and 2.75% 
respectively. 
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Table.4: ENZYME ACTIVITY VALUES OF QUALITY CONTROL 
SERA 
 
Serum Enzyme 
activity 
Mean Standard Deviation 
Cholinesterase (U/L) 7820 ±33.13 
Paraoxonase (U/L) 197.87 ±4.68 
Arylesterase (kU/L) 62.31 ±2.32 
 
Table.4 represents the mean and standard deviation values of Quality 
Control (QC) sera enzyme activities used to plot Levey Jennings chart for 
Quality Control management. The values were not influenced by the 
addition of 15% of ethylene glycol. 
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Figure.11: QUALITY CONTROL CHARTS FOR ENZYME ACTIVITIES 
 
Figure.11.1: Levey Jennings Chart for serum Cholinesterase activity.       
x axis- Days; y axis- mean, ±1SD, ±2SD values of enzyme activity. 
  
 Figure.11.1 depicts the Levey Jennings Chart (LJ chart) for serum 
Cholinesterase activity of QC sera measured for 20 days which was used for 
Quality Control Management on daily basis. 
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Figure.11.2 shows the Levey Jennings Chart (LJ chart) for serum 
Paraoxonase activity of QC sera measured for 20 days which was used for 
Quality Control Management on daily basis 
Figure.11.2: Levey Jennings Chart for serum Paraoxonase activity.           
x axis- Days; y axis- mean, ±1SD, ±2SD values of enzyme activity. 
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Figure.11.3 shows the Levey Jennings Chart (LJ chart) for serum 
Paraoxonase activity of QC sera measured for 20 days which was used for 
Quality Control Management on daily basis. 
 
 
Figure.11.3: Levey Jennings Chart for serum Arylesterase activity.            
x axis- Days; y axis- mean, ±1SD, ±2SD values of enzyme activity. 
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Table.5: DISTRIBUTION OF VALUES OF ANALYTES FOR 
SCREENING AMONG STUDY POPULATION 
Analytes Minimum Maximum Mean SD 
Serum Total Protein (g/dL) 6.4 7.3 6.85 ±0.16 
Random Plasma Glucose    
(mg %) 
74 126 89.63 ±12.46 
 
 Table.5 shows the mean and standard deviation values of Serum Total 
Protein and Random Plasma Glucose of the study population. The minimum 
and maximum values are within the expected reference range. 
 
 
 Figure.12 is the graphical representation of distribution range of 
serum total Protein values amongst the study population. It shows that 95% 
of the OPC poisoning patients have
6.53 – 7.17 g/dL.  
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 serum total protein values between 
 
  
 Table.6: AGE DISTRIBUTION 
PATIENTS 
Age in years 
18-27 
28-37 
38-47 
48-57 
Total 
 Table.6 and Figure.1
which is expressed in percent. 70.4% of the study population belongs to the 
productive age group of 
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AMONGST OPC POISONING 
No. of patients Percent (%)
18 33.4
20 37
8 14.8
8 14.8
54 100
3 shows the Age distribution of study population 
18 – 37 years  . 
 
 
 
 
 
 
 
 Table.7: GENDER DISTRIBUTION AMONGST OPC POISONING 
PATIENTS 
Gender 
Males 
Females 
Total 
 Table.7 and Figure
victims of acute OPC poisoning. 63% of acute OPC poisoning patients are 
males. 
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No.of patients Percent 
34 63
20 37
54 100
.14 shows the distribution of gender amongst the 
(%) 
 
 
 
 
 Table.8: EDUCATIONAL STATUS AMONGST VICTIMS OF OP 
POISONING 
Educational status 
Illiterate 
Primary 
Secondary 
Total 
 Table.8 and Figure.
amongst the study population. 53.7% of patients are literates. 
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No. of patients Percent (%)
25 46.3
3 5.6
26 48.1
54 100
15 shows the distribution of Educational status 
 
 
 
 
 
 
 
 Table.9: MARITAL STATUS AMONGT OPC POISONING PATIENTS
Marital status 
Unmarried 
Married 
Total 
 
 Table.9 and Figure.
poisoning. 64.8% or more than two thirds of patients are married.
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No. of patients Percent (%)
19 35.2
35 64.8
54 100
16 represents the marital status of victims of OPC 
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Table.10: OCCUPATIONAL STATUS OF VICTIMS OF OP POISONING 
Occupational status No. of patients Percent (%) 
Student 6 11.1 
Own Business 9 16.7 
Private job 14 25.9 
Govt.Job 2 3.7 
Farmer 9 16.7 
House wife 9 16.7 
Others 5 9.3 
Total 54 100.0 
 
 
 
  Table.10 and Figure.
of acute OPC poisoning patients. 11.1% are students and 16.7% are farmers. 
25.9% of patients are being in private job. 
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17 are the representation of Occupational status 
 
 
 Table.11: SOCIOECONOMIC STATUS AMONGST OP POISONING 
PATIENTS 
Socioeconomic status
Lower 
Middle 
Upper 
Total 
 
Table.11 and Figure.
study population.57.4% belongs to middle income group 
status. 
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 No. of patients Percent (%)
21 38.9
31 57.4
2 3.7
54 100.0
18 shows Socioeconomic status amongst the 
of socioeconomic 
 
 
 
 
 
 
 Table.12: DOMICILE 
PATIENTS 
Domicile 
Rural 
Suburban 
Urban 
Total 
Table.12 and Figure.1
study population.57.4% of patients are residing in urban
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DISTRIBUTION AMONGST OPC POISONING 
No. of patients Percent (%)
12 22.2
11 20.4
31 57.4
54 100.0
9 represents the domicile distribution amongst the 
 areas. 
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Table.13: ASSOCIATION BETWEEN SERUM PARAOXONASE AND 
ARYLESTERASE ACTIVITIES OF SERUM PARAOXONSE1 ENZYME 
 
Variables Coefficient 
of 
Correlation 
(r) 
Level of 
Significance 
(p) 
Strength of 
Association 
Interpretation 
Sr.Paraoxonse 
vs 
Sr.Arylesterase 
+0.301 < 0.05 Moderate 
association 
Significant 
with positive 
correlation 
 
 Table.13 shows the level and strength of association of serum 
Paraoxonase activity with serum Arylesterase activity of serum PON1 
enzyme. Both enzymes are positively correlated with weak strength of 
association. The coefficient of determination (r2) is +0.09. 
 
 
 
 
 Figure.20 is the graphical representation of association 
Serum Paraoxonase and Arylesterase activities of Serum Paraoxonse1 
enzyme. 
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between 
 Figure.21 is the cumulative frequency graph which shows the tr
distribution of study population by the ratio of serum Paraoxonase to 
Arylesterase activity. This trimodal distribution represents the phenotypes of 
Serum Paraoxonsae1 enzyme by the antimodes at 3.0 and 6.9 as AA, AB, 
BB respectively. 
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imodal 
  Figure.22 is the diagrammatic representation of the distribution of 
PON1 phenotypes among the study population due serum Paraoxonase1 
polymorphism that affects the enzyme activity.
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 Table.14: DISTRIBUTION OF SERUM PON1 PHENOTYPES 
AMONGST OPC POISONING PATIENTS.
PON1 phenotype 
AA 
AB 
BB 
Total 
 Table.14 and Figure
phenotypes among the OPC poisoning patients. 64.8% of study population 
has shown to have AA phenotype of serum PON1 enzyme.
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No. of patients Percent (%)
35 64.8
17 31.5
2 3.7
54 100.0
 23 shows the distribution of serum PON1 
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Table.15: DISTRIBUTION OF SERUM PON1 PHENOTYPES WITH 
RESPECT TO AGE GROUP OF THE STUDY POPULATION 
Age in 
years 
PON1 AA 
No. of patients 
PON1 AB 
No. of patients 
PON1 BB 
No. of patients Total 
18-27 12 5 1 18 
28-37 14 6 0 20 
38-47 4 4 0 8 
48-57 5 2 1 8 
Total 35 17 2 54 
  
 Table.15 shows the distribution of serum PON1 phenotypes with 
respect to age of the OPC poisoning patients. Among all age group, more 
than 60% of patients belong to PON1 AA phenotype.  
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Table.16: DISTRIBUTION OF SERUM PON1 PHENOTYPES WITH 
RESPECT TO GENDER OF THE STUDY POPULATION 
Gender 
PON1 AA 
No. of patients 
PON1 AB 
No. of patients 
PON1 BB 
No. of patients Total 
Males 21 12 1 34 
Females 14 5 1 20 
Total 35 17 2 54 
 
Table.16 represents the distribution of serum PON1 phenotypes with 
respect to gender of the OPC poisoning patients. Serum PON1 phenotypes 
are equally distributed in both males and females. 
 
 Figure.24 shows the serum Paraoxonase activity among the PON1 
phenotypes. Phenotype BB has shown to have high paraoxonase activity.
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 Figure.25 is the diagrammatic representation of serum Arylesterase 
activity among PON1 phenotypes. Phenotype BB has shown to have 
relatively lower Arylesterase activity.
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Table.17: ASSOCIATION OF SERUM PARAOXONASE AND 
ARYLESTERASE ACTIVITIES WITH SERUM PARAOXONSE1 
POLYMORPHISM 
 
 
 
Table.17 shows the level and degree of association of serum 
Paraoxonase and Arylesterase activities with serum PON1 phenotypic 
polymorphism.  
 
 
 
 
 
 
 
 
Variables Coefficient 
of 
Correlation 
(r) 
Level of 
Significance 
(p) 
Strength of 
Association 
Interpretation 
Sr.Paraoxonse vs 
Sr.PON1polymorphism 
+0.653 < 0.0001 Strong 
association 
Significant 
with positive 
correlation 
Sr.Arylesterase vs 
Sr.PON1polymorphism 
-0.306 <0.05 Moderate  
association 
Significant 
with negative 
correlation 
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Table.18: ENZYME ACTIVITIES OF STUDY POPULATION 
 
 
 
Table.18 gives the values of serum Cholinesterase, Paraoxonase, 
Arylesterase enzyme activities of the study population. 
 
 
 
 
 
 
 
 
 
Serum 
Enzyme 
activity 
Minimum Maximum Mean Standard 
Deviation 
Cholinesterase 
(U/L) 
342 9840 2325 ±2027.19 
Paraoxonase 
(U/L) 
49.86 494.28 218.39 ±124.30 
Arylesterase 
(kU/L) 
41.73 191.35 85.13 ±30.19 
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Table.19: ASSOCIATION OF SERUM CHOLINESTERASE ACTIVITY 
WITH SERUM PARAOXONASE AND ARYLESTERASE ACTIVITIES 
 
 
 
 Table.19 shows the association of serum Cholinesterase activity with 
serum Paraoxonase and Arylesterase activities. It shows that serum CHE is 
strongly correlated with serum Paraoxonase allozyme activity of PON1 
enzyme. 
 
 
Variables Coefficient 
of 
Correlation 
(r) 
Level of 
Significance 
(p) 
Strength of 
Association 
Interpretation 
Sr.Cholinesterase 
vs 
Sr.Paraoxonsae 
+0.767 < 0.0001 Strong 
association 
Significant 
with positive 
correlation 
Sr.Cholinesterase  
vs 
Sr.Arylesterase 
-0.239 > 0.05 Weak 
association 
Not 
Significant 
with negative 
correlation 
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 Figure.26 and 27 are the graphical representation of association of 
serum Cholinesterase activity with serum Paraoxonase and Arylesterase 
activities of PON1 enzyme. 
 
 
 
Table.20: ASSOCIATION OF SERUM CHOLINESTERASE ACTIVITY 
WITH RATIO OF SERUM PARAOXONASE/ ARYLESTERASE 
ACTIVITY 
 
 
 
Table.20 is the representation for the strong positive association of 
serum Cholinesterase activity with the ratio of serum Paraoxonase/ 
Arylesterase activity 
 
Variables Coefficient 
of 
Correlation 
(r) 
Level of 
Significance 
(p) 
Strength of 
Association 
Interpretation 
Sr.Cholinesterase 
vs Sr.P/A ratio 
+0.955 < 0.0001 Strong 
association 
Significant 
with positive 
correlation 
  
Figure.28 shows the strong linear positive relationship of serum CHE 
with the ratio of serum Paraoxonase / Arylesterase (P/A) activity.
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Table.21:  MEAN VALUES OF ENZYME ACTIVITIES AMONG 
SERUM PON1 PHENOTYPES OF THE STUDY POPULATION 
 
 
 
 
 Table.21 shows the mean values of serum Cholinesterase, 
Paraoxonase, Arylesterase enzyme activities among serum PON1 
phenotypes of acute OPC poisoning patients 
 
 
 
 
 
 
Serum Enzyme 
activity 
PON1AA PON1AB PON1BB 
Cholinesterase 
(U/L) 
1227.4 3794.94 9052.5 
Paraoxonase 
(U/L) 
160.77 313.01 422.32 
Arylesterase 
(kU/L) 
91.61 74.71 60.31 
  Figure.29 represents the serum CHE activity among the PON1 
phenotypes of acute OPC poisoning patients
 
 
 
 
 
 
 
92 
 
 
93 
 
Table.22: COMPARISON OF MEAN VALUES OF ENZYME 
ACTIVITIES AMONG SERUM PON1 PHENOTYPES 
 
Variables (Activity) F distribution Level of Significance 
Serum 
Cholinesterase 
89.28 < 0.0001 
Serum Paraoxonase 19.18 < 0.001 
Serum Arylesterase 2.65 0.08 
Serum P/A ratio 85.94 < 0.0001 
 
 Table.22 shows the ‘one way ANOVA’ test to compare the mean 
values of enzyme activities among serum PON1 phenotypes. Mean values of 
Serum Cholinesterase activity and ratio of serum Paraoxonase/Arylesterase 
activity are significant among PON1phenotypes at the < 0.0001 level. 
 
 
 
 
  Figure.30 emphasizes
Cholinesterase activity along with seru
serum PON1 phenotypes of acute OPC poisoning patients.
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 the positive linear relationship of Serum 
m Paraoxonase activity among the 
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Table.23: CORRELATION OF SERUM CHOLINESTERASE ACTIVITY 
AND SERUM PARAOXONASE1 PHENOTYPES 
 
 
 
Table.23 shows the correlation between serum Cholinesterase activity 
and serum Paraoxonase1 phenotypes. 
 
Pearson correlation coefficient (r) value of +0.857 denotes the strong 
positive correlation between serum Cholinesterase activity and serum 
Paraoxonase1 phenotypes among the acute OPC poisoning patients. The 
relationship between the two variables is significant at the <0.0001 level. 
 
 
 
 
    
 
             
 
Variables Coefficient 
of 
Correlation 
(r) 
Level of 
Significance 
(p) 
Strength of 
Association 
Interpretation 
Sr.Cholinesterase  
vs Sr.PON1 
phenotypes 
+0.857 < 0.0001 Strong 
association 
Significant 
with positive 
correlation 
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DISCUSSION 
 Organophosphorous (OPC) poisoning whether intentional or 
accidental is one of the leading causes of morbidity and mortality worldwide 
especially in developing countries like India17,19. Acute OPC poisoning is a 
clinical emergency in which the early diagnosis and treatment are crucial72. 
 The main mechanism of OPC toxicity involves the inhibition of 
Cholinesterase and Neuropathy Target Esterase activity (NTE) which leads 
to different grades of neuromuscular toxicity and various stages of paralysis 
which occur in different time interval.4,5. It also increases the oxidative stress 
that damages the nervous and muscular tissues6,7. 
 The exposure to OPCs can be diagnosed early by the detailed history 
and clinical features of OPC poisoning and confirmed by biochemical 
analysis of Cholinesterase activity and urine metabolites of OPCs8. The 
toxicity level of OPC poisoning can be detected from the direct 
measurement of blood level of OPCs which is practically difficult to follow 
as a routine procedure.   
 Though RBC cholinesterase is specific to confirm the exposure to 
OPCs, Serum Cholinesterase activity is a sensitive diagnostic alternative for 
neuronal AChE activity9 and has an advantage in monitoring the disease 
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progression during management by serial estimation of enzyme activity8. 
 In spite of the advances in diagnosis and treatment of OPC poisoning, 
the outcome is still guarded because of the three different phases of the 
poisoning72. Although the acute cholinergic crisis (Type I paralysis) is the 
earliest manifestation of acute organophosphorous compound poisoning, it is 
the intermediate syndrome (Type II paralysis) which has high degree of 
mortality5. Some patients may develop OPC induced delayed neuropathy 
(OPIDN), the type III paralysis which usually occurs after 10 days of 
exposure6,7.   
 It has been postulated that there is a phenomenon called “reinhibition 
of oxime reactivated acetyl cholinesterases” due to persistent high 
concentration of OPC which nullifies the effectiveness of oximes34. Hence 
the severity of OPC poisoning is decided by the degree and duration of 
inhibition of cholinesterase activity. It depends on the level of active oxon 
forms of OPC and is directly related to the activity of serum Paraoxonase1 
enzyme that detoxifies the active OP compounds. These findings have been 
found to be reported in chronic OPC poisoning studies13,15.   
 Sogorb MA., et al conducted studies in experimental animals and 
reported that the blood and tissue concentrations of organophosphates were 
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lowered by the action of mammalian Paraoxonase1 which has a beneficial 
role in OPC poisoning71,75.  Since the serum PON1 is a polymorphic 
enzyme, the inherent detoxifying ability is highly variable among 
individuals and it affects the susceptibility of a patient to OPC toxicity15,16. 
 Eckerson HW, et al reported that the trimodal distribution of serum 
PON1 phenotypes can be identified by the ratio of allozyme activities of 
PON112. Though it was shown that the classification based on the ratio was 
reliable, recent studies found that it can also be differentiated by individual 
Paraoxonase and Arylesterase activities of PON115.  
 In the present study, we assessed the relationship of serum PON1 
phenotypes with serum cholinesterase activity among ‘Acute’ OPC poisoned 
patients. The individual allozyme activities of PON1 and their association 
with each other were analyzed to identify the reliability of serum 
PON1phenotyping based on their ratio. We also evaluated the socio 
demographic profile to assess the pattern of OPC poisoning in the area 
where the study was conducted. 
 From the present study, it has been observed that most of the study 
population belongs to the productive age group of 18 – 37 years . Among the 
study population, 63% were males. Around 53.7 % of the population were 
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educated and majority of them were married. Most of the patients were from  
middle income group residing in urban area. The above socio demographic 
data reflect the pattern of OPC poisoning commonly seen in our hospital 
setup. 
 From the results obtained, it has been observed that serum PON1 has 
two different activities based on the substrate ‘Paraoxon’ and 
‘phenylacetate’ used for in vitro analysis of enzyme activity. Paraoxonase 
activity was highly variable with wide variation in values than Arylesterase 
activity of PON1 in an individual. The association between paraoxonase and 
arylesterase activities of PON1 in the study population was moderately 
correlated with each other.  
 It has been found that only 9% of  variability in paraoxonase activity 
can be explained by the variations in arylesterase activity. This shows that 
PON1 has bimodal and unimodal distribution of phenotypes according to its 
paraoxonase and arylesterase activities respectively as reported in earlier 
studies12,13. This indicates that the PON1 activity is contributed by ‘two’ 
alleles of the genome.  
 The association between paraoxonase and arylesterase activities also  
substantiates the statement of Abessolo FA., et al (2012) that the substrate 
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‘Paraoxon’ is the one which differentiates the activities of the two alleles of 
a single enzyme58. 
It has been observed that the ratio of paraoxonase and arylesterase 
activities revealed the trimodal distribution of serum PON1 as having three 
degrees of enzyme activities which proved the presence of phenotypic 
polymorphism contributed by two alleles which are inherited as a 
‘codominant’ mendelian trait12.  The existence of three phenotypes of serum 
PON1 such as AA, AB and BB was observed at the level of antimodes 3.0 
and 6.9 which has been recently reported in India by Mahesh Harishchandra 
Hampe et al (2014)68. 
 Eckerson., et al reported that PON1 AA, PON1 AB, PON1 BB 
phenotypes have low, intermediate and high paraoxonase/arylesterase 
activity ratio respectively12,13 . It was explained that the variations in the ratio 
of the enzyme activities was mainly influenced by the increase in the levels 
of ‘paraoxonase’ activity. The similar results were observed in the present 
study. 
 The Arylesterase activity of PON1 was observed to be in decreasing 
order from PON1 AA to PON1 BB phenotypes. However the variations in 
arylesterase activity were relatively low among the phenotypes which were 
also shown by various authors on PON1 polymorphism58. It was explained 
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that the variation in activity of arylesterase was relatively less affected 
compared to Paraoxonase activity by the serum PON1 polymorphism12,13,68. 
The distribution of PON1 phenotype is highly variable worldwide60. 
In the present study, PON1 AA phenotype was found to be the predominant 
form and accounts for 64.8% of study population whereas the PON1 AB and 
BB phenotypes were found in 31.5% and 3.7%  of patients respectively. It 
showed that the PON1 AA was the principal form of phenotype in our 
region which was equally distributed among all the age group and gender of 
our study population which showed the inheritance of PON1 is ‘autosomal’ 
dominant12,13.  
It has been observed that the Cholinesterase activity has positive 
correlation with the paraoxonase activity and the ratio of allozyme activities 
of PON1.  From the ‘one way ANOVA’ test, it has been shown that 
cholinesterae activity is stronghly associated with the ratio of 
paraoxonase/arylesterase than paraoxonase activty. It has also been observed 
by the Pearson coefficient of correlation analysis where the ‘r’ value for 
CHE vs Paraoxonase activity was +0.767 and for CHE vs 
Paraoxonase/arylesterase activity ratio was +0.955. It showed the reliability 
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of the allozymic activity ratio for PON1 phenotyping and in the prediction of 
cholinesterase activity12,68. 
In the present study we observed that PON1 AA has low level of 
serum paraoxonase and cholinesterase activity. PON1 AB has intermediate 
activity while PON1 BB has the highest level of paraoxonase and 
cholinesterase activity by estimating the ratio of allozyme activities of PON1 
to determine the PON1 phenotypes. Akgür SA.,et al reported the positive 
correlation of cholinesterase activity with PON1 phenotypes by estimation 
of paraoxonase activity of PON1 in chronic OPC poisoning15.  
From the present study it has been observed that the Pearson 
correlation coefficient of Serum cholinesterase vs serum PON1 phenotypes 
was +0.857 with p value of <0.0001. It indicates the strong positive linear 
relationship of serum cholinesterase with PON1 phenotypic polymorphism. 
It was evident that serum PON1 phenotype AA has less ability to 
detoxify the OPCs due their low level of paraoxonase activity leads to 
incresed inhibition of CHE therby the individuals with PON1 AA were more 
susceptible to OPC toxicity15.  
From this study, it has been shown that serum PON1 phenotyping is 
useful in the identification of susceptible patients to OPC toxicity. Hence the 
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dosage and duration of oxime therapy and the time period for follow up 
management can be modified according to their susceptibility so as to ensure 
better prognosis. 
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CONCLUSION 
 From the present study, it can be concluded that Phenotypic 
polymorphism of Serum Paraoxonase1 has strong association with serum 
Cholinesterase activity thereby has an influence on the patient’s 
susceptibility to OPC toxicity in Acute organophosphorous compound 
poisoning. Serum PON1 AA phenotype has low paraoxonase activity with 
low serum Cholinesterase activity. Serum PON1 BB phenotype has high 
paraoxonase and Cholinesterase activity.  
 This relationship supports the need for routine identification of serum 
Paraoxonase1 phenotype along with the measurement of serum 
Cholinesterase activity in patients with acute OPC poisoning. This will help 
the early detection of susceptibility to OPC toxicity. Hence the management 
can be planned according to their susceptibility and to ensure better 
prognosis.   
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ANNEXURE I 
CLINICAL ASSESSMENT PROFORMA 
 
Name :                                                Age/Sex :                                  IP. No : 
Admission date :                               Discharge date :                    Data No : 
History of presenting illness : 
Past History : 
Personal/Socio demographic History : 
 
General Examination : 
Consciousness :  Orientation :  Pupils :                                          
Vital Signs : 
Temp :                           PR :                         RR :                        BP : 
Systemic Examination : 
Nervous system:     Cardiovascular system: 
Respiratory system:    Abdomen: 
Investigations:  
1. Serum Total Protein: 
 
2. Random Plasma Glucose: 
 
3. Serum Cholinesterase activity: 
 
4. Serum Paraoxonase (salt stimulated) activity of PON1: 
 
5. Serum Arylesterase activity of PON1: 
 
ANNEXURE II 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S 
ANNEXURE III 
MASTER CHART - I 
SOCIO DEMOGRAIC DATA 
S.No Age 
(yrs) 
Gender 
(M/F) 
Education 
(IL/P/S) 
Marital 
status 
Occupation 
Status 
Socio 
economic 
Domicile 
1 32 M S M private M Urban 
2 24 M S UM own  U Suburban 
3 26 M S UM student M Urban 
4 38 M IL M others M Urban 
5 52 M IL M farmer L Rural 
6 32 M IL M private  L Rural 
7 20 M S UM student M Urban 
8 19 F S UM student L Urban 
9 26 M S M own  M Urban 
10 18 F S UM student M Urban 
11 25 F IL M farmer M Rural 
12 27 M IL M farmer M Rural 
13 34 M IL M others M Suburban 
14 35 M S M private  M Suburban 
15 38 F IL M house  L Rural 
16 26 M S UM private  L Suburban 
17 22 M S UM Govt M Urban 
18 28 F S M house  M Urban 
19 39 M IL M farmer M Rural 
20 27 M IL UM others M Suburban 
21 46 F IL M private  L Suburban 
22 35 F S M house  M Rural 
23 57 F IL M house  M Urban 
24 30 M IL M own  U Urban 
25 29 M S UM private  L Urban 
26 28 M IL UM others M Rural 
27 31 F S M house M Urban 
28 54 M P M own  M Urban 
29 40 F IL M farmer M Rural 
30 28 M S M student M Urban 
31 29 M S UM private  L Urban 
32 33 F S M Govt L Urban 
33 35 F IL M farmer L Rural 
34 40 M IL M private  M Urban 
35 22 F S M house  L Urban 
36 30 F IL M house  L Urban 
37 48 M P M own  M Urban 
38 26 M S UM private  M Rural 
39 21 M S UM private  L Urban 
40 35 M S UM own  M Urban 
41 25 F S UM private  L Urban 
42 50 M IL M house  L Urban 
43 29 M S UM private  M Suburban 
44 47 M IL M others L Suburban 
45 36 M IL M own  L Urban 
46 24 F S UM student L Urban 
47 46 F IL M private  L Urban 
48 56 F IL M house L Urban 
49 52 M P M private M Suburban 
50 48 F IL M farmer M Suburban 
51 35 M S M own  M Urban 
52 37 M S M own  M Urban 
53 23 M IL UM farmer L Suburban 
54 28 M IL UM farmer M Urban 
 
Age in years 
Gender: M- Male; F- Female; 
Educational status: IL-Illiterate; P- Primary; S- Secondary   
Marital status: UM- Unmarried; M- Married 
Socioeconomic status: L- Lower; M- Middle; U- Upper 
 
 
 
MASTER CHART - II 
ANALYTICAL VALUES OF STUDY POPULATION 
S.No Age 
(yrs) 
Gender 
(M/F) 
Sr.TP 
(g%) 
RPG 
(mg%) 
Sr.CHE 
(U/L) 
Sr.Para 
(P)(U/L) 
Sr.Aryl 
(A)(kU/L) 
P/A 
ratio 
PON1 
pheno 
1 32 M 6.6 90 2856 180.91 51.38 3.5 AB 
2 24 M 6.9 126 634 83.93 90.83 0.9 AA 
3 26 M 7 119 342 49.86 95.52 0.5 AA 
4 38 M 7.2 82 3512 250.23 62.26 4 AB 
5 52 M 6.6 88 2698 262.56 81.84 3.2 AB 
6 32 M 6.8 90 2462 173.39 57.49 3 AB 
7 20 M 6.9 104 947 148.92 145.28 1 AA 
8 19 F 6.8 92 1232 277.47 153.04 1.8 AA 
9 26 M 6.9 112 1198 192.64 109.45 1.8 AA 
10 18 F 6.9 90 2386 372.15 100.47 3.7 AB 
11 25 F 6.6 86 9840 494.28 70.43 7 BB 
12 27 M 6.7 90 1056 108.91 67.81 1.6 AA 
13 34 M 6.9 92 2912 370.47 102.25 3.6 AB 
14 35 M 6.9 80 1112 170.78 130.37 1.3 AA 
15 38 F 6.4 84 1364 210.86 93.14 2.3 AA 
16 26 M 6.8 80 1346 213.78 97.44 2.2 AA 
17 22 M 7 115 7583 487.92 78.68 6.2 AB 
18 28 F 6.9 98 4206 433.23 93.97 4.6 AB 
19 39 M 6.8 88 2451 225.58 72.02 3.1 AB 
20 27 M 7.1 85 1285 254.88 121.72 2.1 AA 
21 46 F 6.9 76 816 79.91 78.11 1 AA 
22 35 F 6.8 78 2069 405.99 144.38 2.8 AA 
23 57 F 6.9 94 1082 94.56 89.04 1.1 AA 
24 30 M 7 93 1934 112.78 46.33 2.4 AA 
25 29 M 7 80 995 90.22 80.47 1.1 AA 
26 28 M 6.8 90 1468 142.31 67.96 2 AA 
27 31 F 6.7 118 1361 222.25 104.54 2.1 AA 
28 54 M 6.9 83 8265 350.37 50.18 7 BB 
29 40 F 6.5 82 1156 214.57 98.02 2.1 AA 
30 28 M 6.8 81 7265 458.1 75.86 6 AB 
31 29 M 6.9 83 973 52.47 47.35 1.1 AA 
32 33 F 6.9 123 2560 220.8 71.04 3.1 AB 
33 35 F 6.9 85 1215 113.87 48.17 2.4 AA 
34 40 M 6.8 74 3320 203.37 52.13 3.9 AB 
35 22 F 6.9 76 1632 201.99 97.63 2.1 AA 
36 30 F 6.6 78 1791 119.19 53.33 2.2 AA 
37 48 M 6.8 76 1567 135.67 51.82 2.6 AA 
38 26 M 7 88 3713 227.6 54.15 4.2 AB 
39 21 M 7 87 435 56.1 73.53 0.8 AA 
40 35 M 7.3 83 3682 322.14 77.96 4.1 AB 
41 25 F 6.9 86 2781 292.06 84.36 3.4 AB 
42 50 M 6.8 80 1872 306.02 135.71 2.3 AA 
43 29 M 6.7 107 927 101.96 83.92 1.2 AA 
44 47 M 6.9 85 4872 419.64 80.5 5.2 AB 
45 36 M 7 84 398 54.71 87.26 0.6 AA 
46 24 F 7.1 85 1772 196.22 93.08 2.1 AA 
47 46 F 6.8 88 1173 85.24 76.38 1.1 AA 
48 56 F 6.5 90 5255 421.03 73.78 5.7 AB 
49 52 M 6.9 86 1739 181.29 81.8 2.2 AA 
50 48 F 6.9 88 1250 152.89 66.41 2.3 AA 
51 35 M 6.8 98 981 73.8 61.4 1.2 AA 
52 37 M 6.9 90 1178 408.91 191.35 2.1 AA 
53 23 M 6.9 76 1209 106.34 41.73 2.5 AA 
54 28 M 6.8 78 1450 205.68 102.02 2 AA 
 
P/A ratio: SerumParaoxonase/Arylesterase activities Ratio 
PON1 pheno: Serum PON1 phenotype 
 
 
 
 
 
 
 

